Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis
This study will evaluate long-term safety of etanercept with or without other DMARDs in children with polyarticular course or systemic juvenile rheumatoid arthritis (JRA) compared to a cohort of subjects with polyarticular or systemic JRA receiving methotrexate with or without other DMARDs.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Phase IV Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis|
- Adverse event rates and severity [ Time Frame: 36 months of observation ] [ Designated as safety issue: Yes ]
- Growth data and Tanner scores [ Time Frame: 36 months of observation ] [ Designated as safety issue: Yes ]
|Study Start Date:||June 2000|
|Study Completion Date:||January 2008|
|Primary Completion Date:||January 2008 (Final data collection date for primary outcome measure)|
Includes subjects being treated with methotrexate alone or in combination with other DMARDs with the exception of etanercept.
Etanercept alone, etanercept plus methotrexate or other DMARDs
Please refer to this study by its ClinicalTrials.gov identifier: NCT00078793